Labcorp stock dips as 2026 guidance and 2029 growth outlook take center stage

Published on 09/10/2026 at 16:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Labcorp stock trades lower on September 10, 2026 as the company reaffirms 2026 guidance and outlines revenue growth of 5% to 8% per year through 2029. Analysts maintain a Moderate Buy view with a consensus price target of USD 330.00.

Aquarellbild eines gläsernen Bürogebäudes vor Skyline in Pastelltönen — Aquarellmalerei einer Stadtlandschaft mit gläsernem Firmensitz symbolisiert Labcorp, ISIN US50540R4092, im Gesundheitssektor, Illustration mit AI erstellt.

Labcorp stock (ISIN US50540R4092) is trading slightly lower on September 10, 2026 after the company reaffirmed its 2026 guidance and set out a long-term financial outlook through 2029 with targeted revenue growth of 5% to 8% per year and adjusted earnings per share growth of 8.5% to 11.5% per year, according to Stock Titan.

Investor Day puts 2026 guidance and 2029 targets in focus

At its 2026 Investor Day in Burlington, North Carolina on September 10, 2026, Labcorp presented an in-depth review of its growth strategy and innovation roadmap and reaffirmed its financial guidance for fiscal year 2026, according to Labcorp. The company expects 2026 enterprise revenue between USD 14,710 million and USD 14,827 million, implying growth of 5.4 percent to 6.3 percent compared with 2025 revenue of USD 13,950 million, as reported by Investing.com. For 2026 adjusted earnings per share, Labcorp is guiding to a range of USD 18.10 to USD 18.55, which is above the 2025 adjusted EPS base and slightly ahead of a consensus estimate of USD 18.01 cited by Benzinga.

Within the enterprise guidance, the Diagnostics Laboratories segment is expected to generate 2026 revenue between USD 11,450 million and USD 11,532 million, corresponding to growth of 5.3 percent to 6.0 percent year over year, while the Biopharma Laboratory Services segment is forecast to deliver revenue between USD 3,269 million and USD 3,300 million with growth of 5.5 percent to 6.5 percent over 2025, according to Stock Titan. The company also reaffirmed expectations for 2026 free cash flow between USD 1,240 million and USD 1,360 million, a range highlighted by Dow Jones Newswires.

Beyond 2026, Labcorp’s management outlined a long-term outlook through 2029 that targets compound annual revenue growth of 5 percent to 8 percent and compound annual adjusted EPS growth between 8.5 percent and 11.5 percent, supported by adjusted operating margin expansion of 75 to 150 basis points by the end of 2029 and free cash flow growth broadly in line with adjusted earnings growth, as summarized by Bloomberg. For investors, these multi-year targets give visibility on how specialty testing, biopharma services and operational efficiency are expected to combine to drive mid-single-digit to high-single-digit top-line growth and double-digit EPS growth.

Analysts keep a Moderate Buy stance and lift price targets

Analyst sentiment toward Labcorp stock remains constructive. According to MarketBeat, 12 Wall Street analysts currently cover the stock with a consensus rating of Moderate Buy, comprising 9 Buy ratings and 3 Hold ratings. The average twelve-month price target stands at USD 330.00, with a high target of USD 360.00 and a low target of USD 300.00; the consensus target is only slightly above a recent price near USD 326.83 in that overview, which implies modest upside potential from that level. In separate data compiled by PriceTargets.com, the same group of 12 analysts also shows a Moderate Buy consensus with an identical average price target of USD 330.00 and a high forecast of USD 360.00 from JPMorgan Chase & Co. and a low forecast of USD 300.00 from Evercore.

Recent months have seen several upward revisions to individual price targets as analysts factor in Labcorp’s post-spin portfolio and margin trajectory. For example, PriceTargets.com notes that JPMorgan Chase & Co. raised its target from USD 330.00 to USD 360.00 while maintaining an Overweight rating on July 31, 2026, and Morgan Stanley increased its target from USD 308.00 to USD 338.00 on the same date, also with an Overweight stance. Mizuho set a target of USD 355.00 on August 10, 2026, while Piper Sandler nudged its Neutral target from USD 300.00 to USD 309.00 on August 4, 2026. Taken together, these actions support the idea that the Street sees Labcorp’s 2026 guidance and 2029 outlook as broadly credible even if near-term upside from current levels is moderate.

Some alternative views exist on expected returns. An AI-based forecasting model from AltIndex assigns Labcorp an AI Score of 69 out of 100 with a Buy signal and projects a six-month price target of USD 362.29, indicating potential upside of 12.8 percent from a referenced price of USD 321.10 as of early September 2026. While such machine-learning forecasts are not a substitute for fundamental analysis, they underscore that quantitative models also see room for the shares to appreciate if the company delivers on its growth and margin ambitions.

Stock edges lower despite long-term growth ambitions

Labcorp stock trades on the New York Stock Exchange under the ticker LH. As of September 10, 2026 at around 2:36 p.m. Eastern time, the shares were quoted at USD 321.47 on the NYSE, down 1.04 percent from the prior close of USD 324.86, according to price data on a major stock portal. This intraday move leaves the stock roughly in line with the modest downside indicated by some consensus target comparisons, but still close to the upper end of its recent trading range, as the MarketBeat overview implied when it cited a price near USD 326.83 in relation to the USD 330.00 average target.

Market data from the same portal show Labcorp’s one-year price performance above 25 percent and double-digit gains over shorter time horizons, highlighting that the stock has already priced in a significant portion of the company’s post-spin restructuring and organic growth story. For investors, the key question now is whether Labcorp can convert its 2026 guidance and 2029 long-term targets into sustained free cash flow generation and margin expansion; the reiterated 2026 free cash flow range of USD 1,240 million to USD 1,360 million and the targeted 75 to 150 basis points of operating margin expansion through 2029 provide concrete benchmarks against which future quarterly results will be judged.